Wet Age-Related Macular Degeneration
As per the BrightFocus Foundation, nearly 11 million Americans are living with one or other type of Age-Related Macular degeneration (AMD). With approximately 200,000 diagnoses of new cases of Wet Age-Related Macular Degenerationeach year in the U.S., Wet Age-Related Macular Degeneration, also known as neovascular or exudative Wet Age-Related Macular D
egeneration, affects around 1.1 million of the Americans.
Several emerging therapies such as Abicipar Pegol by Allergan, Brolucizumab by Novartis, GB-102 by Graybug Vision, Inc., ALK4290 by Alkahest, Inc., Vorolanib by EyePoint Pharmaceuticals, and FYB201 by Bioeq GmbH are expected to shift the Wet Age-related macular degeneration landscape positively.

Visit to read more: https://www.delveinsight.com/blog/wet-age-related-macular-degeneration/

#pharma #biotech #healthcare #medical #macular #market #marketresearch #lifescience #health